Healthcare operations

Qnovia has obtained a worldwide exclusive license to a novel antimicrobial peptide from the University of Virginia, expanding its biotech portfolio.

CG Oncology announced the publication of pivotal Phase 3 BOND-003 Cohort C study results in The Lancet Oncology, confirming key findings for its cancer therapy.

Ascentage Pharma CEO Dr. Dajun Yang has been recognized in The Medicine Maker Power List 2026, highlighting his influence in pharmaceutical innovation.

Johnson & Johnson has seen a significant increase in media mentions, with 31 mentions in recent coverage, indicating rising global attention.

Vir Biotechnology has filed an 8-K report with the SEC confirming an executive change. Details are limited, and further updates are expected.

New CRISPR-based approach selectively destroys cancer cells, including hard-to-treat types, offering potential for safer, targeted therapies.

Fangzhou has launched Novo Nordisk’s once-weekly basal insulin and GLP-1 therapy in China, expanding access to innovative diabetes treatment.

New approach tests daily postpartum check-ins for first-time mothers discharged early, aiming to improve recovery and reduce risks.

4DMT announces promising 2-year data from its PRISM Phase 2b trial targeting wet AMD, showing sustained efficacy and safety signals in a broad patient population.

The HEALEY ALS Platform Trial Regimen I has completed enrolment, with topline results for NUZ-001 now scheduled for Q2 2027, advancing ALS research.